Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219061 | 0.93 | KDM4E (0.69) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL4074146 | 0.90 | KDM4E (0.65) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL3249853 | 0.88 | CNR1 (0.73) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL2875643 | 0.88 | CNR1 (0.63) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL4791922 | 0.87 | KDM4E (0.57) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL4914356 | 0.86 | GABRA2 (0.60) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL4911810 | 0.84 | GABRA2 (0.58) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL6766067 | 0.83 | MAPT (0.74) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL7977816 | 0.83 | CNR1 (0.65) | CNR1KDM4EMEN1MAPTMAPK1 | |
| SCHEMBL4888462 | 0.82 | CNR1 (0.71) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-7875646-B2 | Cannabinoid receptor antagonist; N-{[5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]methyl}-3-cyanobenzenesulfonamide; psychiatric disorder, substance dependence and withdrawal disorder, cognitive disorder, ADD, neurodegenerative diseases, pain, eating disorders, dyslipidemia, ulcer | SANOFI-AVENTIS (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7297710-B1 | Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | PRMT5, PRMT3, PRMT1 | CNR1 93/4885KDM4E 951/4885MEN1 1128/4885 |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT3, PRMT5, PRMT1 | CNR1 8/4885KDM4E 439/4885MEN1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.